Reshma Kewalramani, CEO & President at VERTEX PHARMACEUTICALS INC / MA (VRTX), sold 15,202 shares at $497.00 ($7.6M) on 2024-07-22, disclosed to the SEC on 2024-07-24.
Scheduled sale ($7.6M) by CEO & President under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| VRTX | SELL | 2024-11-12 | $7.8M | — | Filing → |
| VRTX | SELL | 2024-08-01 | $7.7M | — | Filing → |
| VRTX | SELL | 2024-05-29 | $715K | — | Filing → |